Abstract A072: Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial

Background and Objective: Nadir testosterone values following initiation of androgen deprivation therapy have been shown in several studies to be prognostic for outcome, including time to castration-resistant prostate cancer (TTCRPC) and cancer specific survival (CSS). The biologic reasons for this...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2018-08, Vol.78 (16_Supplement), p.A072-A072
Main Authors: Toren, Paul, Hoffman, Azik, Ding, Keyue, Joncas, France-Hélène, Pouliot, Frédéric, Fradet, Yves, Lévesque, Éric, Guillemette, Chantal, Klotz, Laurence
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A072
container_issue 16_Supplement
container_start_page A072
container_title Cancer research (Chicago, Ill.)
container_volume 78
creator Toren, Paul
Hoffman, Azik
Ding, Keyue
Joncas, France-Hélène
Pouliot, Frédéric
Fradet, Yves
Lévesque, Éric
Guillemette, Chantal
Klotz, Laurence
description Background and Objective: Nadir testosterone values following initiation of androgen deprivation therapy have been shown in several studies to be prognostic for outcome, including time to castration-resistant prostate cancer (TTCRPC) and cancer specific survival (CSS). The biologic reasons for this remain unclear. Using cryopreserved serum from the PR.7 trial of intermittent vs. continuous androgen deprivation therapy(ADT), we determined to assess the role of related sex steroids as prognostic biomarkers in men on androgen deprivation therapy for recurrent cancer post-radiotherapy. Patients and Methods: Canadian patients in the PR.7 trial randomized to the continuous arm were included. Patients were excluded who did not receive ADT(n=3), had
doi_str_mv 10.1158/1538-7445.PRCA2017-A072
format article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1158_1538_7445_PRCA2017_A072</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1158_1538_7445_PRCA2017_A072</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_1158_1538_7445_PRCA2017_A0723</originalsourceid><addsrcrecordid>eNqdUFtOwzAQtBBIlMcZ2Ask2G2jRP2LKhCfVeHfcp1Na2jtaNetyP04GDYqHICv1e7OzM6OEA9KlkpVzaOqZk1Rz-dVuVov26lUddHKenohJn-bSzGRUjZFNa-n1-KG-T21lZLVRHy1G45kbIRMWsAr0vEAjJ_AESm4jsEwDBS2PnB0FjYuHAx9IDE4D4OJDn1kILToTs5vwfguodEXHQ7kTgkQPMQdkhlG6ANl6JEosbIsRxMRrPEWCYbUFmQ6F874BbQ_Q9gFm4TNfmTHEPqsB6t1WUMkZ_Z34qo3e8b7c70V9fPT2_KlsOkAE_Y6OUmuR62kzqHpHI3O0ejf0HT-f_Z_5jcXwXwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Abstract A072: Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial</title><source>EZB Free E-Journals</source><creator>Toren, Paul ; Hoffman, Azik ; Ding, Keyue ; Joncas, France-Hélène ; Pouliot, Frédéric ; Fradet, Yves ; Lévesque, Éric ; Guillemette, Chantal ; Klotz, Laurence</creator><creatorcontrib>Toren, Paul ; Hoffman, Azik ; Ding, Keyue ; Joncas, France-Hélène ; Pouliot, Frédéric ; Fradet, Yves ; Lévesque, Éric ; Guillemette, Chantal ; Klotz, Laurence</creatorcontrib><description>Background and Objective: Nadir testosterone values following initiation of androgen deprivation therapy have been shown in several studies to be prognostic for outcome, including time to castration-resistant prostate cancer (TTCRPC) and cancer specific survival (CSS). The biologic reasons for this remain unclear. Using cryopreserved serum from the PR.7 trial of intermittent vs. continuous androgen deprivation therapy(ADT), we determined to assess the role of related sex steroids as prognostic biomarkers in men on androgen deprivation therapy for recurrent cancer post-radiotherapy. Patients and Methods: Canadian patients in the PR.7 trial randomized to the continuous arm were included. Patients were excluded who did not receive ADT(n=3), had &lt;2 years of follow-up (n=2), received exogenous estrogens or glucocorticoids(n=5), or samples were unavailable(n=36). LC-MS/MS was performed using a validated method to simultaneously analyze ten steroids: dehydroepiandrosterone (DHEA), testosterone (T), dihydrotestosterone (DHT), androst-5-ene-β,17β-diol (5-diol), androstenedione (4-dione), androsterone (AD), estrone (E1), estradiol (E2), progesterone, and androstane-3β,17β-diol (3βdiol). Descriptive statistics and correlation analyses were performed, with longitudinal changes categorized as stable, increasing, decreasing, or mixed. The prognostic value of individual steroid tertiles as well as E1:E2, E2:T, and DHT:T ratios were assessed by Kaplan-Meier analysis and Cox proportional hazards adjusted for baseline clinical variables. Outcomes assessed were TTCRPC, CSS, and overall survival (OS). Results: A total of 219 patients were included in the analysis who had a cryopreserved serum available within 2 years of randomization, with 104 patients having 2 subsequent annual samples available for measurement. Values for DHT, T, 4-dione, AD, DHEA, and 5-diol tended to be correlated among samples. Lower DHEA and AD values were significant associated with older age as was lower DHEA and DHT values with poorer performance status. Higher tertiles of E1 and E2 were associated with sooner TTCRP (log-rank, p=0.03, p=0.02, respectively). Similar trends were seen for 4-dione in predicting TTCRPC (log-rank, p=0.07). Upon adjustment, the highest tertile of E2:T had increased hazard ratios (HR) for CSS (HR=2.36, 95% CI I: 0.90-6.21; p=0.08) and TTCRPC (HR=1.70, 95% CI: 0.90-3.23; p=0.10) relative to the lowest tertile. In an analysis of the subset of patients with longitudinal values, increasing levels of AD over time were associated with poorer CSS and OS (log-rank: p=0.04 and p &lt;0.01, respectively). On adjusted analysis, increasing AD levels had a HR for CSS of 3.43 (95% CI: 0.63-18.67; p=0.15) and a HR for OS of 4.75 (95% CI: 1.49-15.17; p &lt;0.01). Limitations include the number of events for some groups. Conclusions: Increased levels of E1, E2, and AD during ADT correlated with adverse TTCRPC and CSS. Serum sex steroids, including both androgens and estrogens, may act as prognostic biomarkers in men receiving ADT for recurrent prostate cancer. Further investigation is warranted to support clinical use. Citation Format: Paul Toren, Azik Hoffman, Keyue Ding, France-Hélène Joncas, Frédéric Pouliot, Yves Fradet, Éric Lévesque, Chantal Guillemette, Laurence Klotz. Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr A072.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/1538-7445.PRCA2017-A072</identifier><language>eng</language><ispartof>Cancer research (Chicago, Ill.), 2018-08, Vol.78 (16_Supplement), p.A072-A072</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Toren, Paul</creatorcontrib><creatorcontrib>Hoffman, Azik</creatorcontrib><creatorcontrib>Ding, Keyue</creatorcontrib><creatorcontrib>Joncas, France-Hélène</creatorcontrib><creatorcontrib>Pouliot, Frédéric</creatorcontrib><creatorcontrib>Fradet, Yves</creatorcontrib><creatorcontrib>Lévesque, Éric</creatorcontrib><creatorcontrib>Guillemette, Chantal</creatorcontrib><creatorcontrib>Klotz, Laurence</creatorcontrib><title>Abstract A072: Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial</title><title>Cancer research (Chicago, Ill.)</title><description>Background and Objective: Nadir testosterone values following initiation of androgen deprivation therapy have been shown in several studies to be prognostic for outcome, including time to castration-resistant prostate cancer (TTCRPC) and cancer specific survival (CSS). The biologic reasons for this remain unclear. Using cryopreserved serum from the PR.7 trial of intermittent vs. continuous androgen deprivation therapy(ADT), we determined to assess the role of related sex steroids as prognostic biomarkers in men on androgen deprivation therapy for recurrent cancer post-radiotherapy. Patients and Methods: Canadian patients in the PR.7 trial randomized to the continuous arm were included. Patients were excluded who did not receive ADT(n=3), had &lt;2 years of follow-up (n=2), received exogenous estrogens or glucocorticoids(n=5), or samples were unavailable(n=36). LC-MS/MS was performed using a validated method to simultaneously analyze ten steroids: dehydroepiandrosterone (DHEA), testosterone (T), dihydrotestosterone (DHT), androst-5-ene-β,17β-diol (5-diol), androstenedione (4-dione), androsterone (AD), estrone (E1), estradiol (E2), progesterone, and androstane-3β,17β-diol (3βdiol). Descriptive statistics and correlation analyses were performed, with longitudinal changes categorized as stable, increasing, decreasing, or mixed. The prognostic value of individual steroid tertiles as well as E1:E2, E2:T, and DHT:T ratios were assessed by Kaplan-Meier analysis and Cox proportional hazards adjusted for baseline clinical variables. Outcomes assessed were TTCRPC, CSS, and overall survival (OS). Results: A total of 219 patients were included in the analysis who had a cryopreserved serum available within 2 years of randomization, with 104 patients having 2 subsequent annual samples available for measurement. Values for DHT, T, 4-dione, AD, DHEA, and 5-diol tended to be correlated among samples. Lower DHEA and AD values were significant associated with older age as was lower DHEA and DHT values with poorer performance status. Higher tertiles of E1 and E2 were associated with sooner TTCRP (log-rank, p=0.03, p=0.02, respectively). Similar trends were seen for 4-dione in predicting TTCRPC (log-rank, p=0.07). Upon adjustment, the highest tertile of E2:T had increased hazard ratios (HR) for CSS (HR=2.36, 95% CI I: 0.90-6.21; p=0.08) and TTCRPC (HR=1.70, 95% CI: 0.90-3.23; p=0.10) relative to the lowest tertile. In an analysis of the subset of patients with longitudinal values, increasing levels of AD over time were associated with poorer CSS and OS (log-rank: p=0.04 and p &lt;0.01, respectively). On adjusted analysis, increasing AD levels had a HR for CSS of 3.43 (95% CI: 0.63-18.67; p=0.15) and a HR for OS of 4.75 (95% CI: 1.49-15.17; p &lt;0.01). Limitations include the number of events for some groups. Conclusions: Increased levels of E1, E2, and AD during ADT correlated with adverse TTCRPC and CSS. Serum sex steroids, including both androgens and estrogens, may act as prognostic biomarkers in men receiving ADT for recurrent prostate cancer. Further investigation is warranted to support clinical use. Citation Format: Paul Toren, Azik Hoffman, Keyue Ding, France-Hélène Joncas, Frédéric Pouliot, Yves Fradet, Éric Lévesque, Chantal Guillemette, Laurence Klotz. Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr A072.</description><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqdUFtOwzAQtBBIlMcZ2Ask2G2jRP2LKhCfVeHfcp1Na2jtaNetyP04GDYqHICv1e7OzM6OEA9KlkpVzaOqZk1Rz-dVuVov26lUddHKenohJn-bSzGRUjZFNa-n1-KG-T21lZLVRHy1G45kbIRMWsAr0vEAjJ_AESm4jsEwDBS2PnB0FjYuHAx9IDE4D4OJDn1kILToTs5vwfguodEXHQ7kTgkQPMQdkhlG6ANl6JEosbIsRxMRrPEWCYbUFmQ6F874BbQ_Q9gFm4TNfmTHEPqsB6t1WUMkZ_Z34qo3e8b7c70V9fPT2_KlsOkAE_Y6OUmuR62kzqHpHI3O0ejf0HT-f_Z_5jcXwXwg</recordid><startdate>20180815</startdate><enddate>20180815</enddate><creator>Toren, Paul</creator><creator>Hoffman, Azik</creator><creator>Ding, Keyue</creator><creator>Joncas, France-Hélène</creator><creator>Pouliot, Frédéric</creator><creator>Fradet, Yves</creator><creator>Lévesque, Éric</creator><creator>Guillemette, Chantal</creator><creator>Klotz, Laurence</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20180815</creationdate><title>Abstract A072: Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial</title><author>Toren, Paul ; Hoffman, Azik ; Ding, Keyue ; Joncas, France-Hélène ; Pouliot, Frédéric ; Fradet, Yves ; Lévesque, Éric ; Guillemette, Chantal ; Klotz, Laurence</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_1158_1538_7445_PRCA2017_A0723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toren, Paul</creatorcontrib><creatorcontrib>Hoffman, Azik</creatorcontrib><creatorcontrib>Ding, Keyue</creatorcontrib><creatorcontrib>Joncas, France-Hélène</creatorcontrib><creatorcontrib>Pouliot, Frédéric</creatorcontrib><creatorcontrib>Fradet, Yves</creatorcontrib><creatorcontrib>Lévesque, Éric</creatorcontrib><creatorcontrib>Guillemette, Chantal</creatorcontrib><creatorcontrib>Klotz, Laurence</creatorcontrib><collection>CrossRef</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toren, Paul</au><au>Hoffman, Azik</au><au>Ding, Keyue</au><au>Joncas, France-Hélène</au><au>Pouliot, Frédéric</au><au>Fradet, Yves</au><au>Lévesque, Éric</au><au>Guillemette, Chantal</au><au>Klotz, Laurence</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abstract A072: Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><date>2018-08-15</date><risdate>2018</risdate><volume>78</volume><issue>16_Supplement</issue><spage>A072</spage><epage>A072</epage><pages>A072-A072</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><abstract>Background and Objective: Nadir testosterone values following initiation of androgen deprivation therapy have been shown in several studies to be prognostic for outcome, including time to castration-resistant prostate cancer (TTCRPC) and cancer specific survival (CSS). The biologic reasons for this remain unclear. Using cryopreserved serum from the PR.7 trial of intermittent vs. continuous androgen deprivation therapy(ADT), we determined to assess the role of related sex steroids as prognostic biomarkers in men on androgen deprivation therapy for recurrent cancer post-radiotherapy. Patients and Methods: Canadian patients in the PR.7 trial randomized to the continuous arm were included. Patients were excluded who did not receive ADT(n=3), had &lt;2 years of follow-up (n=2), received exogenous estrogens or glucocorticoids(n=5), or samples were unavailable(n=36). LC-MS/MS was performed using a validated method to simultaneously analyze ten steroids: dehydroepiandrosterone (DHEA), testosterone (T), dihydrotestosterone (DHT), androst-5-ene-β,17β-diol (5-diol), androstenedione (4-dione), androsterone (AD), estrone (E1), estradiol (E2), progesterone, and androstane-3β,17β-diol (3βdiol). Descriptive statistics and correlation analyses were performed, with longitudinal changes categorized as stable, increasing, decreasing, or mixed. The prognostic value of individual steroid tertiles as well as E1:E2, E2:T, and DHT:T ratios were assessed by Kaplan-Meier analysis and Cox proportional hazards adjusted for baseline clinical variables. Outcomes assessed were TTCRPC, CSS, and overall survival (OS). Results: A total of 219 patients were included in the analysis who had a cryopreserved serum available within 2 years of randomization, with 104 patients having 2 subsequent annual samples available for measurement. Values for DHT, T, 4-dione, AD, DHEA, and 5-diol tended to be correlated among samples. Lower DHEA and AD values were significant associated with older age as was lower DHEA and DHT values with poorer performance status. Higher tertiles of E1 and E2 were associated with sooner TTCRP (log-rank, p=0.03, p=0.02, respectively). Similar trends were seen for 4-dione in predicting TTCRPC (log-rank, p=0.07). Upon adjustment, the highest tertile of E2:T had increased hazard ratios (HR) for CSS (HR=2.36, 95% CI I: 0.90-6.21; p=0.08) and TTCRPC (HR=1.70, 95% CI: 0.90-3.23; p=0.10) relative to the lowest tertile. In an analysis of the subset of patients with longitudinal values, increasing levels of AD over time were associated with poorer CSS and OS (log-rank: p=0.04 and p &lt;0.01, respectively). On adjusted analysis, increasing AD levels had a HR for CSS of 3.43 (95% CI: 0.63-18.67; p=0.15) and a HR for OS of 4.75 (95% CI: 1.49-15.17; p &lt;0.01). Limitations include the number of events for some groups. Conclusions: Increased levels of E1, E2, and AD during ADT correlated with adverse TTCRPC and CSS. Serum sex steroids, including both androgens and estrogens, may act as prognostic biomarkers in men receiving ADT for recurrent prostate cancer. Further investigation is warranted to support clinical use. Citation Format: Paul Toren, Azik Hoffman, Keyue Ding, France-Hélène Joncas, Frédéric Pouliot, Yves Fradet, Éric Lévesque, Chantal Guillemette, Laurence Klotz. Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr A072.</abstract><doi>10.1158/1538-7445.PRCA2017-A072</doi></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 2018-08, Vol.78 (16_Supplement), p.A072-A072
issn 0008-5472
1538-7445
language eng
recordid cdi_crossref_primary_10_1158_1538_7445_PRCA2017_A072
source EZB Free E-Journals
title Abstract A072: Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T15%3A05%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abstract%20A072:%20Serum%20sex%20steroids%20as%20prognostic%20biomarkers%20in%20patients%20receiving%20androgen-deprivation%20therapy%20for%20recurrent%20prostate%20cancer%20post-radiotherapy:%20A%20post%20hoc%20analysis%20of%20the%20PR.7%20trial&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=Toren,%20Paul&rft.date=2018-08-15&rft.volume=78&rft.issue=16_Supplement&rft.spage=A072&rft.epage=A072&rft.pages=A072-A072&rft.issn=0008-5472&rft.eissn=1538-7445&rft_id=info:doi/10.1158/1538-7445.PRCA2017-A072&rft_dat=%3Ccrossref%3E10_1158_1538_7445_PRCA2017_A072%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-crossref_primary_10_1158_1538_7445_PRCA2017_A0723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true